Andrew Thompson

Andrew is a data scientist leading the RAPID-Dx program advance biomarker discovery and validation in post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Previously, he worked at PatientsLikeMe where he led analyses of patient-reported health data and multi-omic biological data to define predictive biomarkers and characterize disease sub-types. During his graduate degree training in neurobiology, Andrew focused on plasticity in the developing visual system, investigating a role for feedback projections in the fine-tuning of circuits during development. Prior to his PhD, Andrew worked with the discovery group at Vanda Pharmaceuticals, where he performed pharmacogenomics research in support of a phase 3 clinical trial and expression profiling studies – all in an effort to elucidate common gene signatures and repurpose existing drugs for new indications. Andrew earned his BS in biology from the University of Maryland and his PhD in biological and biomedical sciences from Harvard University.